Blockage of TNF-α is already used as standard treatment in various autoimmune diseases [35], whereas clinical trials to evaluate blockage of IL-6 and IL-1β in inflammatory diseases and cancer are ongoing [35, 44–46]. Here, IL1B is linked to autoimmune disease.